Cargando…

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus

The purpose of this extension study was to assess the long-term efficacy and safety of gemigliptin 50 mg in patients with type 2 diabetes mellitus (T2DM). Patients with T2DM who had completed the initial 24-week study comparing gemigliptin monotherapy with placebo were eligible to enrol. In the open...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Sae Jeong, Min, Kyung Wan, Gupta, Sandeep Kumar, Park, Joong Yeol, Shivane, Vyankatesh K., Agarwal, Pankaj Kumar, Kim, Doo Man, Kim, Yong Seung, Baik, Sei Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369212/ https://www.ncbi.nlm.nih.gov/pubmed/33081425 http://dx.doi.org/10.4093/dmj.2020.0047

Ejemplares similares

P.0444 The use of prescription analgesics during COVID-19 lockdown in the Netherlands
por: Saeed, H., et al.
Publicado: (2021)

Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus
por: Gutch, Manish, et al.
Publicado: (2017)

P04.44. The association between the use of complementary and alternative medicine in children with demographic indicators and vaccinations
por: Feiler-Mircus, N
Publicado: (2012)

Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy
por: Kim, Da Rae, et al.
Publicado: (2017)

Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models
por: Nam, Dae-Hwan, et al.
Publicado: (2019)

IDF21-0444 Association Between Prior Antidiabetic Therapy and Outcome in Hospitalized COVID-19 Diabetic Subjects
por: Baidya, A., et al.
Publicado: (2022)

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
por: Kim, Sung-Ho, et al.
Publicado: (2016)

Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double‐blind randomized controlled trial (INICOM study)
por: Lim, Soo, et al.
Publicado: (2016)

Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects
por: Cho, Yong-Soon, et al.
Publicado: (2018)

Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome
por: Seo, Jung Beom, et al.
Publicado: (2019)

Current concepts in blood glucose monitoring
por: Khadilkar, Kranti Shreesh, et al.
Publicado: (2013)

Evaluation of Pharmacokinetic Drug Interactions Between Gemigliptin (Dipeptidylpeptidase-4 Inhibitor) and Glimepiride (Sulfonylurea) in Healthy Volunteers
por: Choi, Hee Youn, et al.
Publicado: (2014)

A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study)
por: Kim, Eun Heui, et al.
Publicado: (2020)

Bone mineral density and factors influencing it in Asian Indian population with type 2 diabetes mellitus
por: Kamalanathan, Sadishkumar, et al.
Publicado: (2014)

A prospective study to assess the role of paraoxonase 1 genotype and phenotype on the lipid-lowering and antioxidant activity of statins
por: Godbole, Charuta, et al.
Publicado: (2023)

Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
por: Jung, Gwon-Soo, et al.
Publicado: (2016)

Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction
por: Nguyen, Giang, et al.
Publicado: (2022)

Gemigliptin Inhibits Interleukin-1β–Induced Endothelial-Mesenchymal Transition via Canonical-Bone Morphogenetic Protein Pathway
por: Hong, Oak-Kee, et al.
Publicado: (2020)

Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
por: Choi, Seung Hee, et al.
Publicado: (2017)

Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells
por: Choi, Soon-Youn, et al.
Publicado: (2017)

A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects
por: Kim, Eunwoo, et al.
Publicado: (2019)

Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy
por: Song, Youngmi, et al.
Publicado: (2023)

Heart failure in COVID‐19: the multicentre, multinational PCHF‐COVICAV registry
por: Sokolski, Mateusz, et al.
Publicado: (2021)

Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
por: Lee, Byung Wan, et al.
Publicado: (2023)

Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study
por: Philip, Elizabeth, et al.
Publicado: (2013)

Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system
por: Oh, Hojin, et al.
Publicado: (2021)

Potentiation of endothelium-dependent vasorelaxation of mesenteric arteries from spontaneously hypertensive rats by gemigliptin, a dipeptidyl peptidase-4 inhibitor class of anti-diabetic drug
por: Kim, Hae Jin, et al.
Publicado: (2018)

COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study
por: Götzinger, Florian, et al.
Publicado: (2020)

Blastocyst quality and reproductive and perinatal outcomes: a multinational multicentre observational study
por: Zou, Haowen, et al.
Publicado: (2023)

Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects
por: Jin, Xuanyou, et al.
Publicado: (2020)

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
por: Park, Sang-In, et al.
Publicado: (2015)

Causes and Outcomes of Sepsis in Southeast Asia: A Multinational Multicentre Cross-sectional Study
por: Limmathurotsakul, Direk
Publicado: (2017)

Action Tremor Associated with Lamotrigine Monotherapy
por: Yang, Ji-Hye, et al.
Publicado: (2010)

Is it worthwhile to screen patients with type 2 diabetes mellitus for subclinical Cushing's syndrome?
por: Budyal, Sweta, et al.
Publicado: (2015)

LC3/GABARAPs drive ubiquitin-independent recruitment of Optineurin and NDP52 to amplify mitophagy
por: Padman, Benjamin Scott, et al.
Publicado: (2019)

Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
por: Lee, Nami, et al.
Publicado: (2021)

HGG-52. SUSTAINED RESPONSE TO CRIZOTINIB MONOTHERAPY IN AN INFANT WITH GOPC-ROS1 FUSED CONGENITAL HEMISPHERIC GLIOMA
por: Lulla, Rishi, et al.
Publicado: (2020)

Highlights from the 52nd Seminar of the Korean Society of Gastrointestinal Endoscopy
por: Kim, Eun Young, et al.
Publicado: (2015)

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial
por: Wilkinson, P M, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_7avokbcl3hnkb16lctmdaeo5aj